Back to news list

Share

Breast Cancer Group,Head and Neck Cancer Group,Lung Cancer Group,News

EORTC’s presence at ESMO 2023

17 Oct 2023

New findings and upcoming EORTC trials in lung, head and neck, breast and rare cancers will be presented at ESMO 2023 in Madrid, highlighting EORTC’s commitment to innovative non-commercial cancer research. Seven abstracts have been accepted, with one of them being an oral presentation. Additionally, EORTC’s Scientific Director, Jan Bogaerts, will delve into the realm of pragmatic trials during a special session on Sunday, 22 October 2023. For a comprehensive overview of EORTC’s activities at ESMO, please refer to the table below.

EORTC presentations:

Presentation title Presentation details
Setting International Standards in Analysing Patient-Reported Outcomes and Quality of Life Endpoints (SISAQOL-IMI): Two years update
Madeline Pe, Belgium		 Friday, 20 October 2023 at 2:00 PM
Room: Ávila Auditorium – NCC
Pragmatic Trials
Jan Bogaerts, Belgium		 Sunday, 22 October 2023 at 10:15 AM
Room: León Auditorium – Hall 7

EORTC abstracts accepted at ESMO:

Cancer type Abstract Title Presentation Details & Abstract Number
Breast Cancer EORTC BCG 1984 – NOBLE – Neoadjuvant Olaparib and Durvalumab for patients with BRCA-associated TripLE Negative Breast Cancer.
Emanuel Buhrer, Belgium		 Saturday, 21 October 2023
Type: Poster Display
Abstract Number: 351TiP
Breast Cancer Deep Learning-based prediction of pathologic complete response to neoadjuvant therapy in breast cancer using H&E images and RNA-Seq in the IMMUcan study.
Christian Esposito, France		 Saturday, 21 October 2023
Type: Poster Display
Abstract Number: 2274P
Lung Cancer IMMUcan consortium: focus on the first non-small cell lung cancer (NSCLC) cohort.
Marie Morfouace, Germany		 Saturday, 21 October 2023
Type: Poster Display
Abstract Number: 2266P
Rare Cancers Molecular profiling of 991 prospectively recruited patients with rare cancers in EUROPE: First results of ARCAGEN – a EORTC-SPECTA and EURACAN study.
Marie Morfouace, Germany		 Sunday, 22 October 2023 at 08:30 AM
Type: Mini Oral session
Room: Santander Auditorium – Hall 9
Abstract Number: 132MO
Head and Neck Carcinoma A phase II study of monalizumab and durvalumab in patients with recurrent/metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN): results of the I2 cohort of the EORTC-HNCG-1559 trial (UPSTREAM).
Rachel Galot, Belgium		 Sunday, 22 October 2023
Type: Poster Display
Abstract Number: 935P
Lung Cancer The 1825-EORTC, ALKALINE: Activity of Lorlatinib based on ALK resistance mutations on blood in ALK positive NSCLC patients previously treated with 2nd generation ALK inhibitor.
Laura Mezquita, Spain		 Monday, 23 October 2023
Type: Poster Display
Abstract Number: 1509TiP
Lung Cancer The 1920-EORTC-BIORADON study: Molecular characterization of non-small cell lung cancer (NSCLC) and indoor radon exposure in Europe.
Laura Mezquita, Spain		 Monday, 23 October 2023
Type: Poster Display
Abstract Number: 1508TiP
Back to news list

Related News

  • Professor Benjamin Besse becomes President of EORTC

    26 Jun 2026

  • CCTG, EORTC and UK3CR welcome G7 commitment to accelerate global progress against cancer

    24 Jun 2026

  • EORTC welcomes EU Biotech Act and calls for refinements to enable patient-centred trials

    24 Jun 2026

  • New study confirms a key quality of life tool can be used with adolescents with cancer

    9 Jun 2026

  • “Changing practice, improving lives”: EORTC publishes its Annual Report 2025

    8 Jun 2026

  • This Clinical Trials Day, EORTC announces the upcoming Summit for Clinical Cancer Research

    20 May 2026

  • Long-term EORTC trial challenges assumptions about lymph node radiation therapy in breast cancer

    17 May 2026

  • Multinational study provides new evidence for the value of response-adapted, personalised treatment in Hodgkin lymphoma

    1 May 2026

  • EORTC’s presence at ESTRO 2026

    30 Apr 2026

  • Independent, academic cancer trials are vital to improve patient outcomes worldwide

    28 Apr 2026